DE69521521D1 - Mono- oder polyfunktionelle konjugate von polylysine - Google Patents

Mono- oder polyfunktionelle konjugate von polylysine

Info

Publication number
DE69521521D1
DE69521521D1 DE69521521T DE69521521T DE69521521D1 DE 69521521 D1 DE69521521 D1 DE 69521521D1 DE 69521521 T DE69521521 T DE 69521521T DE 69521521 T DE69521521 T DE 69521521T DE 69521521 D1 DE69521521 D1 DE 69521521D1
Authority
DE
Germany
Prior art keywords
pct
polylysine
diseases
mono
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69521521T
Other languages
English (en)
Other versions
DE69521521T2 (de
Inventor
Michel Geffard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69521521D1 publication Critical patent/DE69521521D1/de
Application granted granted Critical
Publication of DE69521521T2 publication Critical patent/DE69521521T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69521521T 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine Expired - Lifetime DE69521521T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
PCT/FR1995/001517 WO1996015810A1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine

Publications (2)

Publication Number Publication Date
DE69521521D1 true DE69521521D1 (de) 2001-08-02
DE69521521T2 DE69521521T2 (de) 2002-04-25

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521521T Expired - Lifetime DE69521521T2 (de) 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine

Country Status (14)

Country Link
US (1) US6114388A (de)
EP (1) EP0792167B1 (de)
JP (1) JP4128618B2 (de)
AT (1) ATE202487T1 (de)
AU (1) AU694825B2 (de)
CA (1) CA2205557C (de)
DE (1) DE69521521T2 (de)
DK (1) DK0792167T3 (de)
ES (1) ES2161915T3 (de)
FR (1) FR2727117A1 (de)
GR (1) GR3036710T3 (de)
NZ (1) NZ297040A (de)
PT (1) PT792167E (de)
WO (1) WO1996015810A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
US6399071B1 (en) 1997-04-18 2002-06-04 Novartis Ag Neoglycoproteins
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
ATE287278T1 (de) * 1998-07-30 2005-02-15 Sigma Tau Ind Farmaceuti Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung
AU4835200A (en) * 1999-05-10 2000-11-21 Regents Of The University Of California, The Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
EP2363710B1 (de) * 2002-08-08 2015-07-01 Baylor College Of Medicine Isolierung und identifizierung von t-zellen
DE60321363D1 (de) * 2002-08-28 2008-07-10 Millipore Corp Verfahren zur aufreinigung von sequenzierungsreaktionen
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK1868614T3 (da) 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
CA2651328A1 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
ATE545436T1 (de) 2006-12-22 2012-03-15 Croma Pharma Ges M B H Verwendung von thiolierten polysacchariden zum gewebeaufbau
FR2913335B1 (fr) 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (de) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Behandlung kognitiven Abbaus
CA2830970A1 (en) * 2011-04-12 2012-10-18 Nestec S.A. Nutritional compositions including branched chain fatty acids and methods of using same
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
FR3030524B1 (fr) 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
WO2017046172A1 (en) 2015-09-16 2017-03-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.

Also Published As

Publication number Publication date
US6114388A (en) 2000-09-05
FR2727117A1 (fr) 1996-05-24
CA2205557C (en) 2008-07-15
DK0792167T3 (da) 2001-10-29
AU4181196A (en) 1996-06-17
AU694825B2 (en) 1998-07-30
PT792167E (pt) 2001-12-28
NZ297040A (en) 1999-05-28
GR3036710T3 (en) 2001-12-31
EP0792167B1 (de) 2001-06-27
WO1996015810A1 (fr) 1996-05-30
JPH10511643A (ja) 1998-11-10
EP0792167A1 (de) 1997-09-03
ES2161915T3 (es) 2001-12-16
ATE202487T1 (de) 2001-07-15
DE69521521T2 (de) 2002-04-25
FR2727117B1 (de) 1997-02-21
JP4128618B2 (ja) 2008-07-30
CA2205557A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
PL328858A1 (en) Immunogenous peptides
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU2291097A (en) Novel phenanthridines substituted in the 6 position
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DK1082131T3 (da) Immunoregulator
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ES2110258T3 (es) Derivados de 1,3,5(10)-estratrieno activos por via oral.
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
ATE305052T1 (de) Drogen untersuchungssystem
DE69726602D1 (en) Hepatitis b inhibitoren
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted